GYRE
GYRE THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$6.30
+3.37%Year over year
Reported trailing growth
- Revenue
- +13.5%
- EBITDA
- —
- EBIT
- —
- EPS
- -63.6%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -75.3%
- EBITDA
- +16.1%
- EPS
- +39.7%
Three-year CAGR
- Revenue
- +4.5%
- EBITDA
- +17.1%
- EBIT
- +7.7%
- Net income
- +29.7%
- EPS
- +23.3%
- Free cash flow
- +97.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026